Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD

INTRODUCTION: In pivotal trials of patients with autosomal dominant polycystic kidney disease at risk of rapid progression, tolvaptan slowed estimated glomerular filtration rate (eGFR) decline in early-to-moderate (TEMPO 3:4 [NCT00428948]) and moderate- to late-stage (REPRISE [NCT02160145]) chronic...

Descripción completa

Detalles Bibliográficos
Autores principales: Mallett, Andrew J., Perrone, Ronald D., Rangan, Gopala, Hawley, Carmel, El-Damanawi, Ragada, Hiemstra, Thomas F., Arellano, Carolina Townsend, Lee, Jennifer, Torres, Vicente E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071614/
https://www.ncbi.nlm.nih.gov/pubmed/33912753
http://dx.doi.org/10.1016/j.ekir.2021.01.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071614/
https://www.ncbi.nlm.nih.gov/pubmed/33912753
http://dx.doi.org/10.1016/j.ekir.2021.01.014

Ejemplares similares